Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full BodyGlobeNewsWire · Oct 8, 2026
Biofrontera (NASDAQ:BFRI) & Astrazeneca (NYSE:AZN) Critical ContrastDefense World · Oct 5, 2026
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell CarcinomaGlobeNewsWire · Sep 14, 2026
Biofrontera Inc. (BFRI) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 13, 2026
Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research · Aug 13, 2026
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue GrowthGlobeNewsWire · Aug 13, 2026Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.11 | -$0.05 | Beat |
| May 14, 2026 | -$0.18 | -$0.41 | Miss |
| Mar 19, 2026 | $0.20 | $0.50 | Beat |
| Nov 12, 2025 | -$0.60 | -$0.59 | Beat |
| Aug 13, 2025 | -$0.45 | -$0.57 | Miss |
| May 15, 2025 | -$0.22 | -$0.47 | Miss |